Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The prostate cancer gene 3 or PCA3 test has been commercially approved in Europe as a test that provides relevant information associated with the need for a prostate biopsy. It is still awaiting approval in the USA.
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, PCA3, risk | Leave a Comment »
Under the “And this helps me how?” column we can now add the topic of a possible genetic link between endometrial cancer and prostate cancer (maybe).
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: cancer, endometrial, genome, SNP, womb | Leave a Comment »
On May 4 last year, Dan Zenka of the Prostate Cancer Foundation started a campaign to light the White House blue for one night during Prostate Cancer Awareness Week. This year, Malecare has taken up the challenge too.
Filed under: Diagnosis, Living with Prostate Cancer, Prevention, Risk | Tagged: community, effort, Movember, White House | 1 Comment »
Apparently, over the weekend, Active Biotech completed a deal with the Ipsen Group whereby Ipsen will have responsibilities for the development and marketing of tasquinimod everywhere in the world except North and South America and Japan,
Filed under: Drugs in development | Tagged: tasquinimod | 2 Comments »
Researchers at Johns Hopkins have attempted to correlate data on PSA doubling time (PSADT) with data on prostate cancer progression in men being treated with intermittent androgen deprivation therapy (IADT) after biochemical recurrence of prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: androgen deprivation therapy, doubling time, IADT, intermittent, PSA, PSADT | 1 Comment »
A recent report from John Mulhall’s group at Memorial Sloan-Kettering Cancer Center has provided data on the use of surgical implantation of penile prostheses for management of erectile dysfunction after treatment for prostate cancer.
Filed under: Living with Prostate Cancer, Management | Tagged: ED, erectile dysfunction, implant, penile, prosthesis, surgery | Leave a Comment »
A media release issued yesterday by Dr. David Samadi, a specialist in minimally invasive surgery at Mount Sinai Medical Center in New York City, has questioned whether the purpose of prostate cancer screening is to save lives or to prevent progressive prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, outcome, risk, screening, Treatment, tyesting | 6 Comments »
A new article available online in the Journal of Clinical Oncology provides updated data on the 769 men enrolled in the Johns Hopkins active surveillance program since 1995.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active surveillance, Johns Hopkins, outcome, very low-risk | 6 Comments »
Knowledge of the effectiveness and safety of radical prostatectomy as salvage treatment for men with biochemical recurrence after first-line radiation therapy has long been hampered by the fact that most data are based on small series of patients from individual institutions.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: outcome, radiation, radical prostatectomy, salvage, surgery | 1 Comment »
On March 29 we commented on a newly published paper by Drazer et al. dealing with prostate cancer testing in men of 70 years of age and older. Now this same issue has been taken up by Gina Kolata in an article in the New York Times that will certainly have wider reach than our [...]
Filed under: Diagnosis, Risk | Tagged: age, risk, screening, testing | 2 Comments »
According to an article by Hirsch et al. in the inaugural issue of Practical Radiation Oncology (a new journal for radiation oncologists and their staff), there are some small but significant post-operative differences in pelvic anatomy between patients who undergo robot-assisted laparoscopic prostatectomy (RALP) as opposed to standard, open forms of radical prostatectomy.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: laparoscopic, planning, radiation, radical prostatectomy, RALP, robot, Treatment | 2 Comments »
There is an interesting report today from an Italian clinical research team on the outcomes of radical prostatectomy in men with higher than normal PSA levels (i.e., 20 ng/ml and higher) at time of diagnosis. We know that all prostate cancer patients with PSA levels > 20 ng/ml are now customarily classified as having high-risk [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: high, outcome, PSA, radical prostatectomy, very | 1 Comment »
Data to be presented at the annual meeting of the American Academy of Neurology in Hawaii this week have suggested “compelling evidence that Parkinson’s disease is associated with an increased risk of prostate cancer … and that this increased cancer risk also extends to close and distant relatives of individuals with Parkinson’s disease.”
Filed under: Diagnosis, Risk | Tagged: Parkinson's, risk, Utah | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site